Samsung Biologics set to thrive if BIOSECURE bill passes in USA, says analyst
The biopharmaceutical industry has been buzzing over the US government's unveiling of the BIOSECURE bill. Introduced in the House of Representatives in January 2024, the bill mainly aims to restrict federal government funding and/or partnerships with a few Chinese companies deemed a threat to national security.
Samsung Biologics (KRX: 207940), a South Korean biopharma contract development, and manufacturing organization (CDMO), is poised to see huge growth opportunities if the US passes the bill, says pharma analytics company GlobalData.
A list of companies of concern, including the Chinese CDMO giant Wuxi AppTec, is included in the bill. If the bill passes, the government will examine whether any other China-based companies should be added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze